Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Oct 25, 2024 12:55pm
307 Views
Post# 36282278

Short & simple, look at company presentation

Short & simple, look at company presentation I will probably do a longe4 weekend update, ...on the weekend.
For today, a simple request.
Have a careful look at the very recent updsted ( October) , company presentation.
oncolitics biotrch.com
Lot or up- to - date information & exaplanations of progress & potentail markets.
in the wait, have a safe & healthy weekend.
One slide in particular they point out the many colaborations with Roche.
FYI, Roche et.al.,would not endorse the public use of their good name & lead cancer product tecentriq, which is what Onc is currently working with in the goblet studies...without a ton of legal & clinical due diligence.
That endorsement alone, elevates Onc/ Pelareorep well above its present day trading.
Lots of eyes, absolutely.

<< Previous
Bullboard Posts
Next >>